Citations

Clear

626 citation(s) found for "Mehta, SH".

Clinicopathologic Correlations of Jaw Tremor in a Longitudinal Aging Study
Aslam, Sana , Zhang, Nan , Beach, Thomas G. , Driver‐Dunckley, Erika, Mehta, Shyamal H. , Shill, Holly A. , Aslam, Sana , Driver-Dunckley, Erika, Shill, Holly, Aslam, Sana, Adler, Charles H. , Driver‐Dunckley, Erika

Mayo Clinic

Neurology Clinical Practice | September 9, 2022 | Volume: 12 | Issue: 5 | Pages: No page available

10.1212/cpj.0000000000200072 | PMID 36380899 Get It

CLRM-10 METIS (EF-25): A PIVOTAL, RANDOMIZED CONTROLLED STUDY OF TUMOR TREATING FIELDS IN PATIENTS WITH 1–10 BRAIN METASTASES FROM NON-SMALL CELL LUNG CANCER
Brown, Paul D. , Gondi, Vinai , Ahluwalia, Manmeet S. , Ahluwalia, Manmeet S , Mehta, Minesh P.

Mayo Clinic

Neuro-Oncology Advances | August 5, 2022 | Volume: 4 | Issue: Supplement_1 | Pages: i8-i8

10.1093/noajnl/vdac078.030 Get It

Abstract BACKGROUND Tumor Treating Fields (TTFields) are electric fields that disrupt cancer cell division. TTFields treatment showed efficacy in preclinical non-small cell lung cancer (NSCLC) models. Furthermore, TTFields therapy improved survival with a tolerable safety profile in patients with glioblastoma. The objective of the pivotal METIS trial [NCT02831959] is to evaluate the efficacy and safety of TTFields therapy in NSCLC patients with brain metastases. METHODS NSCLC patients (N=270) with 1–10 brain metastases will be randomized 1:1 to stereotactic radiosurgery (SRS) followed by continuous TTFields therapy using NovoTTF-200M (150 kHz, recommended >18 h/day) with best standard of care (BSC) or SRS followed by BSC alone. Follow-ups will be conducted every 2 months until second intracranial progression. Key inclusion criteria are: Karnofsky Performance Status ≥70, new diagnosis of 1 inoperable or 2–10 supra- and/or infratentorial brain metastases from NSCLC amenable to SRS, and optimal therapy for extracranial disease. Key exclusion criteria are: prior whole brain radiotherapy, single operable, or recurrent brain metastases. Primary endpoint is time to first intracranial progression. Secondary endpoints include time to neurocognitive failure, overall survival, radiological response rate (RANO-BM and RECIST V1.1), quality of life, adverse events, time to first/second intracranial progression for patients with 1–4 and 5–10 brain metastases, bi-monthly intracranial progression rate from 2–12 months, and time to second intracranial and distant progression. The study is powered at 80% (2-sided alpha of 0.05) to detect a hazard ratio of 0.57. In July 2021, an independent Data Monitoring Committee (DMC) reviewed the study data and recommended continuation as planned. The trial is currently recruiting at 92 sites in North America, Europe, Israel, mainland China and Hong Kong.
SARS-CoV-2 Brain Regional Detection, Histopathology, Gene Expression, and Immunomodulatory Changes in Decedents with COVID-19
Serrano, Geidy E. , Walker, Jessica E. , Tremblay, Cécilia , Huentelman, Matthew J. , Belden, Christine M. , Goldfarb, Danielle, Shill, Holly A. , Driver‐Dunckley, Erika , Mehta, Shyamal H. , Caselli, Richard J. , Woodruff, Bryan K. , Haarer, Chadwick F., Ruhlen, Thomas, Nguyen, Steve, Schmitt, Dasan, Rapscak, Steven Z., Bime, Christian , Peters, Joseph L., Alevritis, Ellie, Arce, Richard, Glass, Michael J. , Vargas, Daisy, Sue, Lucia I., Intorcia, Anthony J., Nelson, Courtney M. , Oliver, Javon, Russell, Aryck, Suszczewicz, Katsuko E., Borja, Claryssa I., Cline, Madison P. , Hemmingsen, Spencer J, Qiji, Sanaria H., Hobgood, Holly M, Zhang, Haiyu , Solis, Daniel , Montine, Thomas J. , Berry, Gerald J. , Reiman, Eric M. , Röltgen, Katharina , Boyd, Scott D. , Zehnder, James L. , Desforges, Marc , DeTure, Michael , Beach, Thomas G. , Driver-Dunckley, Erika, Berry, Gerald J , Serrano, Geidy E , Piras, Ignazio Stefano , Shprecher, David , Atri, Alireza , Adler, Charles H. , Haarer, Chadwick F., Torres, Marı́a José , Peters, Joseph L, Mizgerd, Joseph P. , Sahoo, Malaya Kumar , Pinsky, Benjamin A. , Talbot, Pierre J. , Dickson, Dennis W.

Mayo Clinic

Journal of Neuropathology & Experimental Neurology | July 12, 2022 | Volume: 81 | Issue: 9 | Pages: 666-695

10.1093/jnen/nlac056 | PMID 35818336 Get It

Abstract Brains of 42 COVID-19 decedents and 107 non-COVID-19 controls were studied. RT-PCR screening of 16 regions from 20 COVID-19 autopsies found SARS-CoV-2 E gene viral sequences in 7 regions (2.5% of 320 samples), concentrated in 4/20 subjects (20%). Additional screening of olfactory bulb (OB), amygdala (AMY) and entorhinal area for E, N1, N2, RNA-dependent RNA polymerase, and S gene sequences detected one or more of these in OB in 8/21 subjects (38%). It is uncertain whether these RNA sequences represent viable virus. Significant histopathology was limited to 2/42 cases (4.8%), one with a large acute cerebral infarct and one with hemorrhagic encephalitis. Case-control RNAseq in OB and AMY found more than 5000 and 700 differentially expressed genes, respectively, unrelated to RT-PCR results; these involved immune response, neuronal constituents, and olfactory/taste receptor genes. Olfactory marker protein-1 reduction indicated COVID-19-related loss of OB olfactory mucosa afferents. Iba-1-immunoreactive microglia had reduced area fractions in cerebellar cortex and AMY, and cytokine arrays showed generalized downregulation in AMY and upregulation in blood serum in COVID-19 cases. Although OB is a major brain portal for SARS-CoV-2, COVID-19 brain changes are more likely due to blood-borne immune mediators and trans-synaptic gene expression changes arising from OB deafferentation.
Olfactory Bulb Amyloid-β Correlates With Brain Thal Amyloid Phase and Severity of Cognitive Impairment
Tremblay, Cécilia , Intorcia, Anthony J., Mariner, Monica, Sue, Lucia I., Arce, Richard, Belden, Christine M. , Shill, Holly A. , Driver‐Dunckley, Erika, Mehta, Shyamal H. , Beach, Thomas G. , Driver-Dunckley, Erika, Serrano, Geidy E. , Atri, Alireza , Adler, Charles H. , Driver‐Dunckley, Erika

Mayo Clinic

Journal of Neuropathology & Experimental Neurology | June 25, 2022 | Volume: 81 | Issue: 8 | Pages: 643-649

10.1093/jnen/nlac042 | PMID 35751438 Get It

Abstract The Alzheimer disease (AD) neuropathological hallmarks amyloid β (Aβ) and tau neurofibrillary (NF) pathology have been reported in the olfactory bulb (OB) in aging and in different neurodegenerative diseases, which coincides with frequently reported olfactory dysfunction in these conditions. To better understand when the OB is affected in relation to the hierarchical progression of Aβ throughout the brain and whether OB pathology might be an indicator of AD severity, we assessed the presence of OB Aβ and tau NF pathology in an autopsy cohort of 158 non demented control and 173 AD dementia cases. OB Aβ was found in less than 5% of cases in lower Thal phases 0 and 1, in 20% of cases in phase 2, in 60% of cases in phase 3 and in more than 80% of cases in higher Thal phases 4 and 5. OB Aβ and tau pathology significantly predicted a Thal phase greater than 3, a Braak NF stage greater than 4, and an MMSE score lower than 24. While OB tau pathology is almost universal in the elderly and therefore is not a good predictor of AD severity, OB Aβ pathology coincides with clinically-manifest AD and might prove to be a useful biomarker of the extent of brain spread of both amyloid and tau pathology.
Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors
Lassman, Andrew B. , Hoang‐Xuan, Khê , Polley, Mei‐Yin C. , Cairncross, J. Gregory , Ashby, Lynn S., Taphoorn, Martin , Souhami, Luís, Dinjens, Winand N.M. , Kouwenhoven, Mathilde C.M. , Fink, Karen, French, Pim J. , Macdonald, David R., Lacombe, Denis , Won, Minhee , Gorlia, Thierry, Bent, Martin J. van den , Taphoorn, Martin J B , Dinjens, Winand N M , Laack, Nadia N Issa , Kouwenhoven, Mathilde C M , French, Pim J , Mehta, Minesh P , van den Bent, Martin J , Brandes, Alba Ariela , Kros, Johan M. , Laack, Nadia N. , Mehta, Minesh P.

Mayo Clinic

Journal of Clinical Oncology | June 22, 2022 | Volume: 40 | Issue: 23 | Pages: 2539-2545

10.1200/jco.21.02543 | PMID 35731991 Get It

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the basis of the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. Anaplastic oligodendroglial tumors (AOTs) are chemotherapy-sensitive brain tumors. We report the final very long-term survival results from European Organization for the Research and Treatment of Cancer 26951 and Radiation Therapy Oncology Group 9402 phase III trials initiated in 1990s, which both studied radiotherapy with/without neo/adjuvant procarbazine, lomustine, and vincristine (PCV) for newly diagnosed anaplastic oligodendroglial tumors. The median follow-up duration in both was 18-19 years. For European Organization for the Research and Treatment of Cancer 26951, median, 14-year, and probable 20-year overall survival rates without versus with PCV were 2.6 years, 13.4%, and 10.1% versus 3.5 years, 25.1%, and 16.8% (N = 368 overall; hazard ratio [HR] 0.78; 95% CI, 0.63 to 0.98; P = .033), with 1p19q codeletion 9.3 years, 26.2%, and 13.6% versus 14.2 years, 51.0%, and 37.1% (n = 80; HR 0.60; 95% CI, 0.35 to 1.03; P = .063), respectively. For Radiation Therapy Oncology Group 9402, analogous results were 4.8 years, 16.5%, and 11.2% versus 4.8 years, 29.1%, and 24.6% (N = 289 overall; HR 0.79; 95% CI, 0.61 to 1.03; P = .08), with codeletion 7.3 years, 25.0%, and 14.9% versus 13.2 years, 46.1%, and 37% (n = 125; HR 0.61; 95% CI, 0.40 to 0.94; P = .02), respectively. With that, the studies show similar long-term survival even without tumor recurrence in a significant proportion of patients after first-line treatment with radiotherapy/PCV.
Major adverse cardiovascular events after diagnosis of myocardial injury and types 1 and 2 myocardial infarction
Knott, Jonathan D , Ola, Olatunde , Akula, Ashok , Mehta, Ramila A. , Dworak, Marshall , Crockford, Erika, Lobo, Ronstan , Rastas, Nicholas, Karturi, Swetha, Wohlrab, Scott, Hodge, David O. , Grube, Eric , Tak, Tahir , Cagin, Charles , Gulati, Rajiv , Jaffe, Allan S. , Sandoval, Yader , Sandoval, Yader , Michieli, Laura De , Grube, Eric, Jaffe, Allan S.

Mayo Clinic

European Heart Journal. Acute Cardiovascular Care | June 18, 2022 | Volume: 11 | Issue: 7 | Pages: 546-557

10.1093/ehjacc/zuac075 | PMID 35715942 Get It

Abstract Aims Limited US outcome data exist among patients with myocardial injury and types 1 and 2 myocardial infarction (MI) evaluated with high-sensitivity cardiac troponin (hs-cTn). Methods and results This is an observational US cohort study of emergency department (ED) patients undergoing hs-cTnT measurement. Cases with ≥1 hs-cTnT increase >99th percentile were adjudicated following the Fourth Universal Definition of MI. Post-discharge major adverse cardiovascular events (MACE) included death, MI, heart failure (HF) hospitalization, stroke or transient ischaemic attack, and new-onset atrial fibrillation or flutter during 2 years follow-up. Among 2002 patients, 857 (43%) had ≥1 hs-cTnT >99th percentile. Among these, 702 (81.9%) had myocardial injury, 64 (7.5%) had type 1 MI, and 91 (10.6%) had type 2 MI. Compared with patients without myocardial injury, type 2 MI [8.4 vs. 50%; adjusted hazard ratio (HR) 2.31, 95% confidence interval (CI) 1.49–3.58] and myocardial injury (8.4 vs. 47%; adjusted HR 3.13, 95% CI 2.39–4.09) had a higher risk of MACE, in large part because of death and HF hospitalizations. Compared with patients with type 1 MI, type 2 MI (23 vs. 50%; adjusted HR 2.24; 95% CI 1.23–4.10) and myocardial injury (23 vs. 47%; adjusted HR 2.02; 95% CI 1.20–3.40) also have a higher risk of MACE. Conclusion Among unselected US ED patients undergoing hs-cTnT measurement, most increases are due to myocardial injury, and type 2 MI is more frequent than type 1 MI. Patients with myocardial injury and type 2 MI have morbid outcomes, in large part due to death and HF.
Abstract CT186: Pharmacokinetic (PK) profile of a novel IKZF1/3 degrader, CFT7455, enables significant potency advantage over other IKZF1/3 degraders in models of multiple myeloma (MM) and the results of the initial treatment cohort from a first-in-human (
Matous, Jeffrey, Mehta-Shah, Neha, Martin, Thomas G. , Richardson, Paul G. , Bhutani, Manisha , Perino, Samantha , Agafonov, Roman V. , Chaturvedi, Prasoon , Class, Bradley, Schnaderbeck, Matthew, Palmer, Michael R., Gorman, Cathleen, Schönborn‐Kellenberger, Oliver , Hoerres, Amanda, Fisher, Stewart L. , Pollock, Roy M. , Mahler, Michelle, Bardeja, Jesus, Lonial, Sagar , Richard, Shambavi , Yee, Andrew J , Shah, Urvi A. , Mehta–Shah, Neha , Muchtar, Eli , Ailawadhi, Sikander , Richardson, Paul Gerard Guy , Kirby, Jason, Palmer, Michael R., Crystal, Adam

Mayo Clinic

Cancer Research | June 15, 2022 | Volume: 82 | Issue: 12_Supplement | Pages: CT186-CT186

10.1158/1538-7445.am2022-ct186 Get It

Abstract Introduction: CFT7455 is a highly potent and novel Ikaros Family Zinc Finger Protein 1/3 (IKZF1/3) degrader. In xenograft models, CFT7455 has more potent IKZF1/3 degradation compared to other degraders. Early observations from the FIH clinical trial (NCT04756726) along with supporting translational studies are presented here. Methods: Pre-clinical studies comparing CFT7455 and CC-92480 in both in vitro and xenograft models were performed. The pre-clinical studies’ results coincided with observations from the on-going clinical trial. The clinical trial is an open-label, Phase 1/2, multi-center, FIH study in heavily pretreated relapsed/refractory (R/R) MM and non-Hodgkin’s lymphoma (NHL) patients evaluating safety, tolerability, and PK of CFT7455. Eligible MM patients are R/R to therapy and are not candidates for regimens known to provide clinical benefit. A starting dose of 50 μg QD 21 days on/7 days off (21/7) in 28-day cycles was administered. Results: CFT7455 and CC-92480 showed similar cereblon binding profiles and in vitro IKZF1/3 degradation kinetics, translating into sub-nanomolar GI50 values in proliferation assays across a panel of MM cell lines. In the NCI-H929 xenograft model, 100 μg/kg/day of CFT7455 resulted in durable tumor regressions, while 1000 μg/kg/day of CC-92480 gave tumor stasis. Similar results were seen in a systemic model of MM, MM1.S. Both compounds achieved >95% IKZF3 degradation in tumors 4h post dose. At 48h post dose, CFT7455 was more effective than CC-92480 in maintaining IKZF3 degradation (65% vs. 6% respectively). When levels of CFT7455 and CC-92480 in plasma and tumor were compared, CFT7455 concentrations were > DC80 in tumor 48h post dose, while CC-92480 levels were undetectable in tumor and plasma, demonstrating CFT7455 has longer exposure resulting in sustained IKZF1/3 degradation in pre-clinical models. In cohort A, 5 heavily pre-treated MM patients (pts) received single agent CFT7455. 4 pts have received at least 3 cycles, with 2 pts receiving 5 cycles. Neutropenia (grade 4) was observed in 3/5 pts without coincident fever or infection. Additionally, a 2-4 fold accumulation in plasma CFT7455 exposure at steady state was observed. Early pharmacodynamic (PD) data demonstrates deep persistent degradation of IKZF3 (~100%) and serum free light chain reduction (up to 72%) in response to treatment. Stable disease has been observed in 34 pts, suggesting clinical benefit. Conclusions: While CFT7455 showed clinical benefit at 50 ug with deep target degradation, neutropenia was dose limiting. PK/PD modeling suggests alternative dosing regimens may result in increased tolerability with preserved efficacy, and evaluation of them is underway. Updated results will be presented at the meeting. Citation Format: Sagar Lonial, Shambavi Richard, Jeffrey V Matous, Andrew J. Yee, Urvi Shah, Neha Mehta-Shah, Thomas Martin, Eli Muchtar, Sikander Ailawadhi, Paul G. Richardson, Manisha Bhutani, Samantha Perino, Jason Kirby, Roman V. Agafonov, Prasoon Chaturvedi, Bradley Class, Matthew Schnaderbeck, Michael R. Palmer, Cathleen Gorman, Oliver Schoenborn-Kellenberger, Amanda Hoerres, Stewart L. Fisher, Roy M. Pollock, Adam Crystal, Michelle Mahler, Jesus Bardeja. Pharmacokinetic (PK) profile of a novel IKZF1/3 degrader, CFT7455, enables significant potency advantage over other IKZF1/3 degraders in models of multiple myeloma (MM) and the results of the initial treatment cohort from a first-in-human (FIH) phase 1/2 study of CFT7455 in MM [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr CT186.
INVESTIGATING THE QUALITY OF MACHINE LEARNING RESEARCH AND REPORTING IN HYPERTENSION
Lip, Stefanie , Manandhar, Ishan , Pattnaik, Harsha , Alsanosi, Safaa , Sionakidis, Aristeidis , Le, Nhu Ngoc , Mehta, Dhruven , Kassi, Maria, Rostron, Maggie , Tummala, Ramakumar, Joe, Bina , Alsanosi, Safaa , Toit, Clea du , Tran, Tran , Aryal, Sachin , Sykes, Robert , Deo, Neha , McCallum, Linsay , Stevenson, Leah, Kashyap, Rahul , Padmanabhan, Sandosh

Mayo Clinic

Journal of Hypertension | June 14, 2022 | Volume: 40 | Issue: Suppl 1 | Pages: e78

10.1097/01.hjh.0000835956.81410.5e Get It

Objective: Artificial intelligence and machine learning (AI/ML) are increasingly being applied to big clinical data to tackle research questions that cannot be answered with traditional statistical methods. The field is still in its nascent stages and there is a paucity of guidelines for conducting and reporting AI/ML research in hypertension. The objective was to apply the HUMANE checklist to survey the present landscape of AI/ML in hypertension to inform the development of hypertension-specific guidelines and recommendations. Design and method: The HUMANE checklist was developed by global clinical and AI/ML experts through the Delphi method. It assesses the quality of medical AI/ML articles based on whether they cover subjects expected in any peer-reviewed, clinical or AI/ML research publication. A cooping review was carried out to identify articles presenting original research in AI/ML and hypertension published in 2019–2021. Two independent reviewers applied the checklist to each article and in the case of discordance, the response was adjudicated by an AI/ML expert. Results were analysed to assess compliance with the survey (% of papers satisfying checklist requirements). Results: A total of 63 manuscripts was reviewed. A summary of results is shown in Figure 1. Highest compliance was seen for items relating to general article presentation, with compliance ranging from 68% to 98% (description of statistical analysis methods and background context, respectively). Lowest compliance was seen with checklist items relating to clinical research and AI/ML methods. 44% of reviewed articles described the demographics of their dataset and 48% stated their inclusion/exclusion criteria. Nonetheless, datasets were deemed appropriate for investigative aims in 93% of articles. 30% of manuscripts reported their calibration measures, while 73% stated their performance metrics. Internal validation was carried out in 75% of studies, but external validity was assessed in only 14% of cases. Algorithmic bias was addressed in 11% of papers. Conclusions: Application of AI/ML methods in hypertension research is growing, but the majority of current work has major shortfalls in reporting quality, model validation and algorithmic bias. Our study identifies areas of improvement to enable the full realisation of the potential of AI/ML in hypertension.
Intraabdominal pressure as a marker for physiologic and pathologic processes in pregnancy
Narang, Kavita , Weaver, Amy L. , Mehta, Ramila A. , Szymanski, Linda M. , Szymanski, Linda M , Garovic, Vesna D.

Mayo Clinic

Hypertension in Pregnancy | June 7, 2022 | Volume: 41 | Issue: 3-4 | Pages: 181-189

10.1080/10641955.2022.2085741 | PMID 35669998 Get It

RETRACTED: Effect Comparison of E-Cigarette and Traditional Smoking and Association with Stroke—A Cross-Sectional Study of NHANES
Patel, Urvish , Patel, Neel , Khurana, Mahika , Parulekar, Akshada, Patel, Amrapali , Ortíz, Juan Fernando , Patel, Rutul , Urhoghide, Eseosa, Mistry, Anuja, Bhriguvanshi, Arpita, Abdulqader, Mohammed Ali, Mehta, Neev , Arumaithurai, Kogulavadanan , Shah, Shamik , Patel, Urvish K

Mayo Clinic

Neurology International | May 29, 2022 | Volume: 14 | Issue: 2 | Pages: 441-452

10.3390/neurolint14020037 | PMID 35736618 Get It

Introduction: Tobacco use is one of the most significant risk factors for stroke. Besides traditional cigarettes and combustible products, the use of e-cigarettes and electronic nicotine delivery products has been widespread among young adults in the recent era. Furthermore, the trend of vaping has increased over the last decade. However, the relationship between e-cigarettes and stroke is largely unknown. The aim of this study was to evaluate the prevalence and identify the relationship between e-cigarette smoking and stroke. Methods: A cross-sectional study was performed using the NHANES database of the US population. Adults with a history of smoking were considered in our study and divided into three groups, e-cigarette users, traditional, and dual smokers. The Chi-squared test, Wilcoxon rank-sum test, and multivariable logistic regression analysis were used to identify the prevalence and association of e-cigarette consumption and stroke. Results: Out of a total of 266,058 respondents from 2015 to 2018, we found 79,825 respondents who smoked e-cigarettes (9.72%) or traditional (29.37%) or dual smoking (60.91%). Stroke prevalence among e-cigarette smokers was 1.57%. Stroke was more prevalent among traditional smokers than among e-cigarette smokers. (6.75% vs. 1.09%; p < 0.0001) E-cigarette smokers had early onset of stroke in comparison with traditional smokers. (median age: 48 vs. 59 years; p < 0.0001). Among females with stroke, the prevalence of e-cigarette use was higher in comparison with traditional smoking (36.36% vs. 33.91%; p < 0.0001). Among the stroke population, the prevalence of e-cigarette use was higher among Mexican-Americans (21.21% vs. 6.02%) and other Hispanics (24.24% vs. 7.70%) compared with traditional smoking (p < 0.0001). The regression analysis found higher odds of stroke history among e-cigarette users than traditional smokers [aOR: 1.15; 95% CI: 1.15–1.16)]. Conclusion: Though stroke was more prevalent in traditional smokers, the incidence of stroke was early-in-onset and was strongly associated with e-cigarette use compared to traditional smokers. We have also identified vascular effects of e-cigarettes components as possible triggers for the stroke.